7 years of historical data (2019–2025) · Healthcare · Medical - Equipment & Services
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Hims & Hers Health, Inc. trades at 69.5x earnings, 27% above its 5-year average of 54.6x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 214%. On a free-cash-flow basis, the stock trades at 105.3x P/FCF, 74% above the 5-year average of 60.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.8B | $8.4B | $5.7B | $1.9B | $1.3B | $1.2B | $516M | $344M |
| Enterprise Value | $8.8B | $9.4B | $5.5B | $1.8B | $1.3B | $1.2B | $489M | $323M |
| P/E Ratio → | 69.55 | 63.67 | 45.62 | — | — | — | — | — |
| P/S Ratio | 3.32 | 3.57 | 3.88 | 2.14 | 2.49 | 4.50 | 3.47 | 4.17 |
| P/B Ratio | 16.93 | 15.50 | 12.01 | 5.42 | 4.21 | 3.66 | — | — |
| P/FCF | 105.30 | 113.37 | 28.87 | 39.65 | — | — | — | — |
| P/OCF | 25.96 | 27.95 | 22.81 | 25.36 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Hims & Hers Health, Inc.'s enterprise value stands at 55.1x EBITDA, 14% below its 5-year average of 64.3x. The Healthcare sector median is 14.2x, placing the stock at a 288% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.01 | 3.74 | 2.04 | 2.41 | 4.26 | 3.29 | 3.91 |
| EV / EBITDA | 55.10 | 58.83 | 69.84 | — | — | — | — | — |
| EV / EBIT | 83.54 | 89.19 | 89.12 | — | — | — | — | — |
| EV / FCF | — | 127.36 | 27.82 | 37.80 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Hims & Hers Health, Inc. earns an operating margin of 4.5%. Operating margins have expanded from -3.4% to 4.5% over the past 3 years, signaling improving operational efficiency. ROE of 25.2% indicates solid capital efficiency. ROIC of 8.6% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.8% | 73.8% | 79.5% | 82.0% | 77.6% | 75.2% | 73.6% | 54.0% |
| Operating Margin | 4.5% | 4.5% | 4.2% | -3.4% | -13.0% | -42.3% | -10.2% | -90.1% |
| Net Profit Margin | 5.5% | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | -12.2% | -87.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | 25.2% | 25.2% | 30.7% | -7.2% | -20.3% | -114.7% | — | — |
| ROA | 9.0% | 9.0% | 21.9% | -5.8% | -16.7% | -39.9% | -19.0% | -100.0% |
| ROIC | 8.6% | 8.6% | 17.7% | -8.4% | -19.1% | -183.4% | — | — |
| ROCE | 9.4% | 9.4% | 14.8% | -8.8% | -20.8% | -51.7% | -19.6% | -144.6% |
Solvency and debt-coverage ratios — lower is generally safer
Hims & Hers Health, Inc. carries a Debt/EBITDA ratio of 7.9x, which is highly leveraged (145% above the sector average of 3.2x). Net debt stands at $1.0B ($1.3B total debt minus $229M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.34 | 2.34 | 0.02 | 0.03 | 0.02 | 0.02 | — | — |
| Debt / EBITDA | 7.89 | 7.89 | 0.14 | — | — | — | — | — |
| Net Debt / Equity | — | 1.91 | -0.44 | -0.25 | -0.13 | -0.20 | — | — |
| Net Debt / EBITDA | 6.46 | 6.46 | -2.65 | — | — | — | — | — |
| Debt / FCF | — | 14.00 | -1.05 | -1.85 | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -1514.40 | -194.05 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.90x means Hims & Hers Health, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.00x to 1.90x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.90 | 1.90 | 1.79 | 3.00 | 4.52 | 3.41 | 7.43 | 3.38 |
| Quick Ratio | 1.61 | 1.61 | 1.50 | 2.74 | 4.07 | 3.24 | 7.19 | 3.17 |
| Cash Ratio | 1.43 | 1.43 | 1.36 | 2.50 | 3.75 | 3.12 | 6.58 | 2.93 |
| Asset Turnover | — | 1.09 | 2.09 | 1.98 | 1.44 | 0.65 | 1.25 | 1.15 |
| Inventory Turnover | 5.31 | 5.31 | 4.71 | 6.99 | 5.48 | 4.97 | 11.09 | 9.00 |
| Days Sales Outstanding | — | 5.00 | 1.50 | 2.82 | 2.24 | 4.80 | 1.84 | 3.80 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Hims & Hers Health, Inc. returns 1.2% to shareholders annually primarily through share buybacks. The earnings yield of 1.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.4% | 1.6% | 2.2% | — | — | — | — | — |
| FCF Yield | 0.9% | 0.9% | 3.5% | 2.5% | — | — | — | — |
| Buyback Yield | 1.2% | 1.1% | 1.5% | 0.1% | 0.0% | 1.8% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.2% | 1.1% | 1.5% | 0.1% | 0.0% | 1.8% | 0.0% | 0.0% |
| Shares Outstanding | — | $258M | $237M | $209M | $205M | $187M | $35M | $35M |
Compare HIMS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $8B | 69.5 | 55.1 | 105.3 | 73.8% | 4.5% | 25.2% | 8.6% | 7.9 | |
| $1B | -7.1 | 17.1 | 5.1 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 | |
| $4B | 20.9 | 16.8 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 | |
| $93M | 18.4 | 5.9 | 5.0 | 63.3% | 11.0% | 4.2% | 6.8% | 1.6 | |
| $145B | 148.7 | 64.6 | 50.8 | 39.2% | 3.3% | 2.5% | 0.5% | 8.6 | |
| $192B | 12.2 | 9.1 | 43.2 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 | |
| $1.0T | 47.8 | 34.3 | 115.6 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 | |
| $141M | -1.4 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — | |
| $873M | 130.3 | 138.6 | — | 43.0% | 1.4% | 6.6% | 3.9% | — | |
| $922M | 31.2 | 4.2 | 5.6 | 92.8% | 11.0% | 4.5% | 10.6% | 0.3 | |
| $129M | -0.7 | 17.3 | — | 33.5% | -11.6% | -58.3% | -6.1% | 11.9 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HIMS stock.
Hims & Hers Health, Inc.'s current P/E ratio is 69.5x. The historical average is 54.6x. This places it at the 100th percentile of its historical range.
Hims & Hers Health, Inc.'s current EV/EBITDA is 55.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 64.3x.
Hims & Hers Health, Inc.'s return on equity (ROE) is 25.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -17.2%.
Based on historical data, Hims & Hers Health, Inc. is trading at a P/E of 69.5x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Hims & Hers Health, Inc. has 73.8% gross margin and 4.5% operating margin.
Hims & Hers Health, Inc.'s Debt/EBITDA ratio is 7.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.